- >
- News & Events
- >
- Press Releases
Press Releases
Page 1 of 30
Publication of the 2021 Annual Financial Report
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
04/28/2022
Le Journal des Biotechs | Interview of Shefali Agarwal, President and CEO of Onxeo
Watch the interview (in French)
04/20/2022
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]
04/07/2022
Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]
04/06/2022
Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022
AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]
03/31/2022
Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Paris (France), March 9, 2022 – 7:00 […]
03/09/2022
Onxeo Announces its Financial Agenda for 2022
Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]
01/13/2022
Onxeo appoints Julien Miara as new interim CEO
Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]
01/03/2022
New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments
These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions Paris (France), December 8, 2021 […]
12/08/2021
Onxeo Continues to Strengthen its Board of Directors
Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member Paris […]
11/23/2021
Page 1 of 30